Assuntos
Técnicas de Laboratório Clínico/métodos , Técnicas de Laboratório Clínico/normas , Fungos/isolamento & purificação , Manuais como Assunto/normas , Ciência de Laboratório Médico/métodos , Ciência de Laboratório Médico/normas , Micoses/diagnóstico , Micoses/microbiologia , Antifúngicos/farmacologia , Meios de Cultura , Farmacorresistência Fúngica , Fungos/efeitos dos fármacos , Fungos/genética , Fungos/imunologia , Humanos , Testes Imunológicos , Japão , Técnicas Microbiológicas , Patologia Molecular , Manejo de EspécimesRESUMO
The Japanese Society for Medical Mycology (JSMM) method used for testing the antifungal susceptibility of yeast, the MIC end point for azole antifungal agents, is currently set at IC(80). It was recently shown, however that there is an inconsistency in the MIC value between the JSMM method and the CLSI M27-A2 (CLSI) method, in which the end- point was to read as IC(50). To resolve this discrepancy and reassess the JSMM method, the MIC for three azoles, fluconazole, itraconazole and voriconazole were compared to 5 strains of each of the following Candida species: C. albicans, C. glabrata, C. tropicalis, C. parapsilosis and C. krusei, for a total of 25 comparisons, using the JSMM method, a modified JSMM method, and the CLSI method. The results showed that when the MIC end- point criterion of the JSMM method was changed from IC(80) to IC(50) (the modified JSMM method) , the MIC value was consistent and compatible with the CLSI method. Finally, it should be emphasized that the JSMM method, using a spectrophotometer for MIC measurement, was superior in both stability and reproducibility, as compared to the CLSI method in which growth was assessed by visual observation.
Assuntos
Antifúngicos/farmacologia , Candida/efeitos dos fármacos , Testes de Sensibilidade Microbiana/normas , Japão , Micologia , Sociedades MédicasRESUMO
After the rapid progress in therapeutic pharmaceutics against onychomycosis caused by dermatophytes in the 1990s, an optimal therapeutic strategy for individual patients with the onychomycosis has become possible for clinical dermatologists. In this review, we discuss on clinical problems concerning this disease and propose recommendable treatments for each patient with topical and/or systemic use of antifungal agents. Finally, with consideration of already published therapeutic guidelines, we stress the necessity of "order-made" therapy for each patient with his/her medical status and wishes taking into account.
Assuntos
Antifúngicos/administração & dosagem , Arthrodermataceae , Dermatomicoses/microbiologia , Dermatomicoses/terapia , Itraconazol/administração & dosagem , Micologia , Naftalenos/administração & dosagem , Onicomicose/microbiologia , Onicomicose/terapia , Guias de Prática Clínica como Assunto , Sociedades Médicas , Administração Oral , Administração Tópica , Humanos , Japão , TerbinafinaRESUMO
With the abolition of Leprosy Prevention Act of 1996, that opportunities examining the Hansen's disease patient with a general medical institution increase is expected. Because we experienced Hansen's disease of a staying in Japan foreigner then in such time, we present it. A case is a man of 50 years old, who is a Filipino of 3 years living in Japan. It recognized infiltrating deep erythema in a face and trunk. Furthermore, in dysesthesia, nerve hyperplasia, and Bl is positive in skin smear. Histopathology is a typical finding. Than the above, we diagnosed it as Hansen's disease of BL-LL type.
